Results for 'cutaneous'
Oncology approvals in 2020: a year of firsts in the midst of a pandemic
Jan 29th • 4 mins read
Inadequate and delayed characterization of cutaneous reactions for US Food and Drug Administration-approved oncologic drugs from 2011-2020 leading to medication discontinuation
Oct 23rd • 4 mins read